CEL-SCI Corporation $2.5M Stock Offering
Analysis based on 6 articles · First reported Jun 14, 2026 · Last updated Jun 16, 2026
The market impact on CEL-SCI Corporation is generally neutral to slightly positive, as the offering provides capital for continued development and operations, which could support future growth. However, the dilution from new shares could offset immediate stock price gains.
CEL-SCI Corporation, a clinical-stage cancer immunotherapy company, announced the pricing and subsequent closing of a best-efforts public offering. The company sold 2,500,000 shares of common stock at $1.00 per share, generating gross proceeds of $2.5 million. ThinkEquity served as the sole placement agent for the offering. The proceeds are earmarked for the ongoing development of Multikine, general corporate purposes, and working capital. The securities were offered under a shelf registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard